The Future of HIV Therapy: GAMMORA
GAMMORA, developed by Code Pharma, offers a new approach to HIV treatment by effectively eliminating virus-infected cells and promoting the circulation of healthy CD4 cells. Clinical trials have demonstrated that GAMMORA halts the production of the virus by inducing programmed cell death, specifically targeting infected cells while sparing healthy ones. This precise mechanism makes it a promising alternative to traditional HIV therapies that primarily aim to control the virus rather than eradicate infected cells.
How Does It Work?
GAMMORA works by introducing a synthetic peptide into the body. This harmless peptide allows viral DNA to integrate excessively into infected cells, overwhelming their systems. As a result, the infected cells undergo apoptosis, a form of controlled self-destruction, while healthy cells remain unaffected. The destruction of infected cells opens the door for the regeneration of healthy CD4 cells, essential for maintaining a strong immune system.
Clinical studies on GAMMORA have shown significant reductions in HIV-infected cells, coupled with its ability to stop the production of the virus by selectively killing infected cells. Unlike traditional antiretroviral treatments that slow viral replication, GAMMORA offers a more targeted solution by actively reducing the number of HIV-infected cells. The trials have also revealed that GAMMORA has minimal side effects, as it selectively impacts only the infected cells, leaving healthy ones untouched.